PubMed:32161990 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":25,"end":39},"obj":"UBERON:0004535"},{"id":"T2","span":{"begin":40,"end":49},"obj":"GO:0008152"},{"id":"T3","span":{"begin":62,"end":70},"obj":"SP_7"},{"id":"T4","span":{"begin":120,"end":134},"obj":"UBERON:0004535"},{"id":"T5","span":{"begin":135,"end":144},"obj":"GO:0008152"},{"id":"T6","span":{"begin":211,"end":223},"obj":"NCBITaxon:11118"},{"id":"T7","span":{"begin":225,"end":234},"obj":"SP_7"},{"id":"T8","span":{"begin":245,"end":253},"obj":"SP_7"},{"id":"T9","span":{"begin":347,"end":361},"obj":"UBERON:0004535"},{"id":"T10","span":{"begin":362,"end":371},"obj":"GO:0008152"},{"id":"T11","span":{"begin":405,"end":413},"obj":"SP_7"},{"id":"T12","span":{"begin":494,"end":508},"obj":"UBERON:0004535"},{"id":"T13","span":{"begin":509,"end":518},"obj":"GO:0008152"},{"id":"T14","span":{"begin":531,"end":539},"obj":"SP_7"},{"id":"T15","span":{"begin":823,"end":838},"obj":"UBERON:0002037"},{"id":"T16","span":{"begin":877,"end":885},"obj":"SP_7"},{"id":"T17","span":{"begin":967,"end":982},"obj":"UBERON:0002037"},{"id":"T18","span":{"begin":1163,"end":1171},"obj":"SP_7"},{"id":"T19","span":{"begin":1191,"end":1198},"obj":"UBERON:0000948"},{"id":"T20","span":{"begin":1230,"end":1237},"obj":"UBERON:0000948"},{"id":"T21","span":{"begin":1372,"end":1386},"obj":"UBERON:0004535"},{"id":"T22","span":{"begin":1387,"end":1396},"obj":"GO:0008152"},{"id":"T23","span":{"begin":1537,"end":1545},"obj":"SP_7"},{"id":"T24","span":{"begin":1566,"end":1574},"obj":"SP_7"},{"id":"T25","span":{"begin":1617,"end":1622},"obj":"UBERON:0000948"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PAS-Enju","denotations":[{"id":"EnjuParser_T0","span":{"begin":0,"end":10},"obj":"NN"},{"id":"EnjuParser_T1","span":{"begin":11,"end":14},"obj":"CC"},{"id":"EnjuParser_T2","span":{"begin":15,"end":21},"obj":"NN"},{"id":"EnjuParser_T3","span":{"begin":22,"end":24},"obj":"IN"},{"id":"EnjuParser_T4","span":{"begin":25,"end":39},"obj":"JJ"},{"id":"EnjuParser_T5","span":{"begin":40,"end":49},"obj":"JJ"},{"id":"EnjuParser_T6","span":{"begin":50,"end":58},"obj":"NNS"},{"id":"EnjuParser_T7","span":{"begin":59,"end":61},"obj":"IN"},{"id":"EnjuParser_T8","span":{"begin":62,"end":70},"obj":"NN"},{"id":"EnjuParser_T9","span":{"begin":71,"end":73},"obj":"IN"},{"id":"EnjuParser_T10","span":{"begin":74,"end":79},"obj":"NNP"},{"id":"EnjuParser_T11","span":{"begin":81,"end":91},"obj":"NN"},{"id":"EnjuParser_T12","span":{"begin":91,"end":92},"obj":"-COLON-"},{"id":"EnjuParser_T13","span":{"begin":93,"end":100},"obj":"NNS"},{"id":"EnjuParser_T14","span":{"begin":101,"end":105},"obj":"VBP"},{"id":"EnjuParser_T15","span":{"begin":106,"end":114},"obj":"VBN"},{"id":"EnjuParser_T16","span":{"begin":115,"end":119},"obj":"IN"},{"id":"EnjuParser_T17","span":{"begin":120,"end":134},"obj":"JJ"},{"id":"EnjuParser_T18","span":{"begin":135,"end":144},"obj":"JJ"},{"id":"EnjuParser_T19","span":{"begin":145,"end":158},"obj":"NNS"},{"id":"EnjuParser_T20","span":{"begin":159,"end":163},"obj":"VBD"},{"id":"EnjuParser_T21","span":{"begin":164,"end":172},"obj":"NNS"},{"id":"EnjuParser_T22","span":{"begin":173,"end":177},"obj":"RBR"},{"id":"EnjuParser_T23","span":{"begin":178,"end":189},"obj":"JJ"},{"id":"EnjuParser_T24","span":{"begin":190,"end":192},"obj":"TO"},{"id":"EnjuParser_T25","span":{"begin":193,"end":199},"obj":"VB"},{"id":"EnjuParser_T26","span":{"begin":200,"end":204},"obj":"CD"},{"id":"EnjuParser_T27","span":{"begin":205,"end":210},"obj":"JJ"},{"id":"EnjuParser_T28","span":{"begin":211,"end":217},"obj":"NN"},{"id":"EnjuParser_T29","span":{"begin":218,"end":223},"obj":"NN"},{"id":"EnjuParser_T30","span":{"begin":224,"end":225},"obj":"-LRB-"},{"id":"EnjuParser_T31","span":{"begin":225,"end":234},"obj":"NN"},{"id":"EnjuParser_T32","span":{"begin":234,"end":235},"obj":"-RRB-"},{"id":"EnjuParser_T33","span":{"begin":236,"end":243},"obj":"NN"},{"id":"EnjuParser_T34","span":{"begin":244,"end":245},"obj":"-LRB-"},{"id":"EnjuParser_T35","span":{"begin":245,"end":253},"obj":"NN"},{"id":"EnjuParser_T36","span":{"begin":253,"end":254},"obj":"-RRB-"},{"id":"EnjuParser_T37","span":{"begin":254,"end":255},"obj":"-COMMA-"},{"id":"EnjuParser_T38","span":{"begin":256,"end":259},"obj":"CC"},{"id":"EnjuParser_T39","span":{"begin":260,"end":271},"obj":"VBD"},{"id":"EnjuParser_T40","span":{"begin":272,"end":275},"obj":"DT"},{"id":"EnjuParser_T41","span":{"begin":276,"end":285},"obj":"NN"},{"id":"EnjuParser_T42","span":{"begin":287,"end":290},"obj":"DT"},{"id":"EnjuParser_T43","span":{"begin":291,"end":294},"obj":"NN"},{"id":"EnjuParser_T44","span":{"begin":295,"end":297},"obj":"IN"},{"id":"EnjuParser_T45","span":{"begin":298,"end":302},"obj":"DT"},{"id":"EnjuParser_T46","span":{"begin":303,"end":311},"obj":"NN"},{"id":"EnjuParser_T47","span":{"begin":312,"end":314},"obj":"VBZ"},{"id":"EnjuParser_T48","span":{"begin":315,"end":317},"obj":"TO"},{"id":"EnjuParser_T49","span":{"begin":318,"end":327},"obj":"VB"},{"id":"EnjuParser_T50","span":{"begin":328,"end":331},"obj":"DT"},{"id":"EnjuParser_T51","span":{"begin":332,"end":343},"obj":"NN"},{"id":"EnjuParser_T52","span":{"begin":344,"end":346},"obj":"IN"},{"id":"EnjuParser_T53","span":{"begin":347,"end":361},"obj":"JJ"},{"id":"EnjuParser_T54","span":{"begin":362,"end":371},"obj":"JJ"},{"id":"EnjuParser_T55","span":{"begin":372,"end":380},"obj":"NNS"},{"id":"EnjuParser_T56","span":{"begin":381,"end":385},"obj":"IN"},{"id":"EnjuParser_T57","span":{"begin":386,"end":389},"obj":"DT"},{"id":"EnjuParser_T58","span":{"begin":390,"end":401},"obj":"NN"},{"id":"EnjuParser_T59","span":{"begin":402,"end":404},"obj":"IN"},{"id":"EnjuParser_T60","span":{"begin":405,"end":413},"obj":"NN"},{"id":"EnjuParser_T61","span":{"begin":415,"end":422},"obj":"NNS"},{"id":"EnjuParser_T62","span":{"begin":422,"end":423},"obj":"-COLON-"},{"id":"EnjuParser_T63","span":{"begin":424,"end":425},"obj":"DT"},{"id":"EnjuParser_T64","span":{"begin":426,"end":439},"obj":"NN"},{"id":"EnjuParser_T65","span":{"begin":440,"end":442},"obj":"IN"},{"id":"EnjuParser_T66","span":{"begin":443,"end":451},"obj":"JJ"},{"id":"EnjuParser_T67","span":{"begin":452,"end":459},"obj":"NNS"},{"id":"EnjuParser_T68","span":{"begin":460,"end":464},"obj":"WDT"},{"id":"EnjuParser_T69","span":{"begin":465,"end":475},"obj":"VBD"},{"id":"EnjuParser_T70","span":{"begin":476,"end":479},"obj":"DT"},{"id":"EnjuParser_T71","span":{"begin":480,"end":490},"obj":"NN"},{"id":"EnjuParser_T72","span":{"begin":491,"end":493},"obj":"IN"},{"id":"EnjuParser_T73","span":{"begin":494,"end":508},"obj":"JJ"},{"id":"EnjuParser_T74","span":{"begin":509,"end":518},"obj":"JJ"},{"id":"EnjuParser_T75","span":{"begin":519,"end":527},"obj":"NNS"},{"id":"EnjuParser_T76","span":{"begin":528,"end":530},"obj":"IN"},{"id":"EnjuParser_T77","span":{"begin":531,"end":539},"obj":"NN"},{"id":"EnjuParser_T78","span":{"begin":540,"end":543},"obj":"CC"},{"id":"EnjuParser_T79","span":{"begin":544,"end":552},"obj":"VBD"},{"id":"EnjuParser_T80","span":{"begin":553,"end":556},"obj":"DT"},{"id":"EnjuParser_T81","span":{"begin":557,"end":567},"obj":"NNS"},{"id":"EnjuParser_T82","span":{"begin":568,"end":570},"obj":"IN"},{"id":"EnjuParser_T83","span":{"begin":571,"end":574},"obj":"DT"},{"id":"EnjuParser_T84","span":{"begin":575,"end":588},"obj":"NNS"},{"id":"EnjuParser_T85","span":{"begin":589,"end":591},"obj":"IN"},{"id":"EnjuParser_T86","span":{"begin":592,"end":602},"obj":"JJ"},{"id":"EnjuParser_T87","span":{"begin":603,"end":606},"obj":"CC"},{"id":"EnjuParser_T88","span":{"begin":607,"end":621},"obj":"JJ"},{"id":"EnjuParser_T89","span":{"begin":622,"end":630},"obj":"NNS"},{"id":"EnjuParser_T90","span":{"begin":631,"end":634},"obj":"VBD"},{"id":"EnjuParser_T91","span":{"begin":635,"end":644},"obj":"VBN"},{"id":"EnjuParser_T92","span":{"begin":646,"end":652},"obj":"NN"},{"id":"EnjuParser_T93","span":{"begin":653,"end":656},"obj":"CC"},{"id":"EnjuParser_T94","span":{"begin":657,"end":663},"obj":"NNP"},{"id":"EnjuParser_T95","span":{"begin":664,"end":668},"obj":"VBD"},{"id":"EnjuParser_T96","span":{"begin":669,"end":677},"obj":"VBN"},{"id":"EnjuParser_T97","span":{"begin":678,"end":681},"obj":"IN"},{"id":"EnjuParser_T98","span":{"begin":682,"end":690},"obj":"JJ"},{"id":"EnjuParser_T99","span":{"begin":691,"end":698},"obj":"NNS"},{"id":"EnjuParser_T100","span":{"begin":700,"end":707},"obj":"NNS"},{"id":"EnjuParser_T101","span":{"begin":707,"end":708},"obj":"-COLON-"},{"id":"EnjuParser_T102","span":{"begin":709,"end":710},"obj":"DT"},{"id":"EnjuParser_T103","span":{"begin":711,"end":716},"obj":"NN"},{"id":"EnjuParser_T104","span":{"begin":717,"end":719},"obj":"IN"},{"id":"EnjuParser_T105","span":{"begin":720,"end":723},"obj":"CD"},{"id":"EnjuParser_T106","span":{"begin":724,"end":731},"obj":"NNS"},{"id":"EnjuParser_T107","span":{"begin":732,"end":736},"obj":"IN"},{"id":"EnjuParser_T108","span":{"begin":737,"end":741},"obj":"CD"},{"id":"EnjuParser_T109","span":{"begin":742,"end":750},"obj":"NNS"},{"id":"EnjuParser_T110","span":{"begin":751,"end":755},"obj":"VBD"},{"id":"EnjuParser_T111","span":{"begin":756,"end":764},"obj":"VBN"},{"id":"EnjuParser_T112","span":{"begin":765,"end":767},"obj":"IN"},{"id":"EnjuParser_T113","span":{"begin":768,"end":772},"obj":"DT"},{"id":"EnjuParser_T114","span":{"begin":773,"end":781},"obj":"NN"},{"id":"EnjuParser_T115","span":{"begin":783,"end":786},"obj":"DT"},{"id":"EnjuParser_T116","span":{"begin":787,"end":798},"obj":"NNS"},{"id":"EnjuParser_T117","span":{"begin":799,"end":801},"obj":"IN"},{"id":"EnjuParser_T118","span":{"begin":802,"end":814},"obj":"NN"},{"id":"EnjuParser_T119","span":{"begin":814,"end":815},"obj":"-COMMA-"},{"id":"EnjuParser_T120","span":{"begin":816,"end":846},"obj":"NN"},{"id":"EnjuParser_T121","span":{"begin":847,"end":850},"obj":"CC"},{"id":"EnjuParser_T122","span":{"begin":851,"end":859},"obj":"NN"},{"id":"EnjuParser_T123","span":{"begin":860,"end":862},"obj":"IN"},{"id":"EnjuParser_T124","span":{"begin":863,"end":871},"obj":"NNS"},{"id":"EnjuParser_T125","span":{"begin":872,"end":876},"obj":"IN"},{"id":"EnjuParser_T126","span":{"begin":877,"end":885},"obj":"NN"},{"id":"EnjuParser_T127","span":{"begin":886,"end":890},"obj":"VBD"},{"id":"EnjuParser_T128","span":{"begin":891,"end":895},"obj":"CD"},{"id":"EnjuParser_T129","span":{"begin":895,"end":896},"obj":"NN"},{"id":"EnjuParser_T130","span":{"begin":896,"end":897},"obj":"-COMMA-"},{"id":"EnjuParser_T131","span":{"begin":898,"end":902},"obj":"CD"},{"id":"EnjuParser_T132","span":{"begin":902,"end":903},"obj":"NN"},{"id":"EnjuParser_T133","span":{"begin":904,"end":907},"obj":"CC"},{"id":"EnjuParser_T134","span":{"begin":908,"end":911},"obj":"CD"},{"id":"EnjuParser_T135","span":{"begin":911,"end":912},"obj":"NN"},{"id":"EnjuParser_T136","span":{"begin":912,"end":913},"obj":"-COMMA-"},{"id":"EnjuParser_T137","span":{"begin":914,"end":926},"obj":"RB"},{"id":"EnjuParser_T138","span":{"begin":928,"end":931},"obj":"DT"},{"id":"EnjuParser_T139","span":{"begin":932,"end":942},"obj":"NNS"},{"id":"EnjuParser_T140","span":{"begin":943,"end":945},"obj":"IN"},{"id":"EnjuParser_T141","span":{"begin":946,"end":958},"obj":"NN"},{"id":"EnjuParser_T142","span":{"begin":958,"end":959},"obj":"-COMMA-"},{"id":"EnjuParser_T143","span":{"begin":960,"end":982},"obj":"JJ"},{"id":"EnjuParser_T144","span":{"begin":983,"end":991},"obj":"NNS"},{"id":"EnjuParser_T145","span":{"begin":992,"end":995},"obj":"CC"},{"id":"EnjuParser_T146","span":{"begin":996,"end":1004},"obj":"NNS"},{"id":"EnjuParser_T147","span":{"begin":1005,"end":1009},"obj":"VBD"},{"id":"EnjuParser_T148","span":{"begin":1010,"end":1015},"obj":"IN"},{"id":"EnjuParser_T149","span":{"begin":1016,"end":1024},"obj":"NNS"},{"id":"EnjuParser_T150","span":{"begin":1024,"end":1025},"obj":"-COMMA-"},{"id":"EnjuParser_T151","span":{"begin":1026,"end":1036},"obj":"NNS"},{"id":"EnjuParser_T152","span":{"begin":1037,"end":1040},"obj":"CC"},{"id":"EnjuParser_T153","span":{"begin":1041,"end":1049},"obj":"NNS"},{"id":"EnjuParser_T154","span":{"begin":1049,"end":1050},"obj":"-COMMA-"},{"id":"EnjuParser_T155","span":{"begin":1051,"end":1063},"obj":"RB"},{"id":"EnjuParser_T156","span":{"begin":1063,"end":1064},"obj":"-COMMA-"},{"id":"EnjuParser_T157","span":{"begin":1065,"end":1071},"obj":"JJR"},{"id":"EnjuParser_T158","span":{"begin":1072,"end":1074},"obj":"IN"},{"id":"EnjuParser_T159","span":{"begin":1075,"end":1085},"obj":"JJ"},{"id":"EnjuParser_T160","span":{"begin":1086,"end":1091},"obj":"NNS"},{"id":"EnjuParser_T161","span":{"begin":1092,"end":1096},"obj":"IN"},{"id":"EnjuParser_T162","span":{"begin":1097,"end":1099},"obj":"IN"},{"id":"EnjuParser_T163","span":{"begin":1100,"end":1105},"obj":"PRP-DOLLAR-"},{"id":"EnjuParser_T164","span":{"begin":1106,"end":1120},"obj":"JJ"},{"id":"EnjuParser_T165","span":{"begin":1121,"end":1133},"obj":"NNS"},{"id":"EnjuParser_T166","span":{"begin":1135,"end":1137},"obj":"IN"},{"id":"EnjuParser_T167","span":{"begin":1138,"end":1143},"obj":"JJS"},{"id":"EnjuParser_T168","span":{"begin":1144,"end":1147},"obj":"CD"},{"id":"EnjuParser_T169","span":{"begin":1147,"end":1148},"obj":"NN"},{"id":"EnjuParser_T170","span":{"begin":1149,"end":1157},"obj":"NNS"},{"id":"EnjuParser_T171","span":{"begin":1158,"end":1162},"obj":"IN"},{"id":"EnjuParser_T172","span":{"begin":1163,"end":1171},"obj":"NN"},{"id":"EnjuParser_T173","span":{"begin":1172,"end":1180},"obj":"VBD"},{"id":"EnjuParser_T174","span":{"begin":1181,"end":1184},"obj":"DT"},{"id":"EnjuParser_T175","span":{"begin":1185,"end":1190},"obj":"JJ"},{"id":"EnjuParser_T176","span":{"begin":1191,"end":1198},"obj":"JJ"},{"id":"EnjuParser_T177","span":{"begin":1199,"end":1205},"obj":"NN"},{"id":"EnjuParser_T178","span":{"begin":1207,"end":1210},"obj":"DT"},{"id":"EnjuParser_T179","span":{"begin":1211,"end":1220},"obj":"NN"},{"id":"EnjuParser_T180","span":{"begin":1221,"end":1223},"obj":"IN"},{"id":"EnjuParser_T181","span":{"begin":1224,"end":1229},"obj":"JJ"},{"id":"EnjuParser_T182","span":{"begin":1230,"end":1237},"obj":"JJ"},{"id":"EnjuParser_T183","span":{"begin":1238,"end":1244},"obj":"NN"},{"id":"EnjuParser_T184","span":{"begin":1245,"end":1248},"obj":"VBD"},{"id":"EnjuParser_T185","span":{"begin":1249,"end":1254},"obj":"IN"},{"id":"EnjuParser_T186","span":{"begin":1255,"end":1257},"obj":"CD"},{"id":"EnjuParser_T187","span":{"begin":1258,"end":1263},"obj":"NNS"},{"id":"EnjuParser_T188","span":{"begin":1264,"end":1270},"obj":"JJR"},{"id":"EnjuParser_T189","span":{"begin":1271,"end":1273},"obj":"IN"},{"id":"EnjuParser_T190","span":{"begin":1274,"end":1284},"obj":"JJ"},{"id":"EnjuParser_T191","span":{"begin":1285,"end":1293},"obj":"NNS"},{"id":"EnjuParser_T192","span":{"begin":1294,"end":1302},"obj":"VBN"},{"id":"EnjuParser_T193","span":{"begin":1303,"end":1307},"obj":"IN"},{"id":"EnjuParser_T194","span":{"begin":1308,"end":1311},"obj":"DT"},{"id":"EnjuParser_T195","span":{"begin":1312,"end":1326},"obj":"JJ"},{"id":"EnjuParser_T196","span":{"begin":1327,"end":1335},"obj":"NNS"},{"id":"EnjuParser_T197","span":{"begin":1337,"end":1347},"obj":"NN"},{"id":"EnjuParser_T198","span":{"begin":1347,"end":1348},"obj":"-COLON-"},{"id":"EnjuParser_T199","span":{"begin":1349,"end":1357},"obj":"NNS"},{"id":"EnjuParser_T200","span":{"begin":1358,"end":1362},"obj":"IN"},{"id":"EnjuParser_T201","span":{"begin":1363,"end":1371},"obj":"JJ"},{"id":"EnjuParser_T202","span":{"begin":1372,"end":1386},"obj":"JJ"},{"id":"EnjuParser_T203","span":{"begin":1387,"end":1396},"obj":"JJ"},{"id":"EnjuParser_T204","span":{"begin":1397,"end":1405},"obj":"NNS"},{"id":"EnjuParser_T205","span":{"begin":1406,"end":1409},"obj":"MD"},{"id":"EnjuParser_T206","span":{"begin":1410,"end":1414},"obj":"VB"},{"id":"EnjuParser_T207","span":{"begin":1415,"end":1416},"obj":"DT"},{"id":"EnjuParser_T208","span":{"begin":1417,"end":1424},"obj":"JJR"},{"id":"EnjuParser_T209","span":{"begin":1425,"end":1429},"obj":"NN"},{"id":"EnjuParser_T210","span":{"begin":1430,"end":1432},"obj":"IN"},{"id":"EnjuParser_T211","span":{"begin":1433,"end":1443},"obj":"VBG"},{"id":"EnjuParser_T212","span":{"begin":1444,"end":1448},"obj":"IN"},{"id":"EnjuParser_T213","span":{"begin":1449,"end":1452},"obj":"DT"},{"id":"EnjuParser_T214","span":{"begin":1453,"end":1459},"obj":"JJ"},{"id":"EnjuParser_T215","span":{"begin":1460,"end":1469},"obj":"NN"},{"id":"EnjuParser_T216","span":{"begin":1470,"end":1473},"obj":"CC"},{"id":"EnjuParser_T217","span":{"begin":1474,"end":1477},"obj":"DT"},{"id":"EnjuParser_T218","span":{"begin":1478,"end":1491},"obj":"NNS"},{"id":"EnjuParser_T219","span":{"begin":1492,"end":1495},"obj":"MD"},{"id":"EnjuParser_T220","span":{"begin":1496,"end":1500},"obj":"RB"},{"id":"EnjuParser_T221","span":{"begin":1501,"end":1508},"obj":"RB"},{"id":"EnjuParser_T222","span":{"begin":1509,"end":1515},"obj":"VB"},{"id":"EnjuParser_T223","span":{"begin":1516,"end":1519},"obj":"DT"},{"id":"EnjuParser_T224","span":{"begin":1520,"end":1529},"obj":"NN"},{"id":"EnjuParser_T225","span":{"begin":1530,"end":1532},"obj":"IN"},{"id":"EnjuParser_T226","span":{"begin":1533,"end":1536},"obj":"DT"},{"id":"EnjuParser_T227","span":{"begin":1537,"end":1545},"obj":"NN"},{"id":"EnjuParser_T228","span":{"begin":1547,"end":1549},"obj":"IN"},{"id":"EnjuParser_T229","span":{"begin":1550,"end":1553},"obj":"DT"},{"id":"EnjuParser_T230","span":{"begin":1554,"end":1559},"obj":"JJ"},{"id":"EnjuParser_T231","span":{"begin":1560,"end":1564},"obj":"NN"},{"id":"EnjuParser_T232","span":{"begin":1564,"end":1565},"obj":"-COMMA-"},{"id":"EnjuParser_T233","span":{"begin":1566,"end":1574},"obj":"NN"},{"id":"EnjuParser_T234","span":{"begin":1575,"end":1578},"obj":"MD"},{"id":"EnjuParser_T235","span":{"begin":1578,"end":1579},"obj":"-COMMA-"},{"id":"EnjuParser_T236","span":{"begin":1580,"end":1582},"obj":"IN"},{"id":"EnjuParser_T237","span":{"begin":1583,"end":1587},"obj":"NN"},{"id":"EnjuParser_T238","span":{"begin":1587,"end":1588},"obj":"-COMMA-"},{"id":"EnjuParser_T239","span":{"begin":1589,"end":1598},"obj":"VBP"},{"id":"EnjuParser_T240","span":{"begin":1599,"end":1602},"obj":"DT"},{"id":"EnjuParser_T241","span":{"begin":1603,"end":1609},"obj":"NN"},{"id":"EnjuParser_T242","span":{"begin":1610,"end":1612},"obj":"TO"},{"id":"EnjuParser_T243","span":{"begin":1613,"end":1616},"obj":"DT"},{"id":"EnjuParser_T244","span":{"begin":1617,"end":1622},"obj":"NN"}],"relations":[{"id":"EnjuParser_R0","pred":"arg1Of","subj":"EnjuParser_T0","obj":"EnjuParser_T1"},{"id":"EnjuParser_R1","pred":"arg2Of","subj":"EnjuParser_T2","obj":"EnjuParser_T1"},{"id":"EnjuParser_R2","pred":"arg1Of","subj":"EnjuParser_T1","obj":"EnjuParser_T3"},{"id":"EnjuParser_R3","pred":"arg2Of","subj":"EnjuParser_T6","obj":"EnjuParser_T3"},{"id":"EnjuParser_R4","pred":"arg1Of","subj":"EnjuParser_T6","obj":"EnjuParser_T4"},{"id":"EnjuParser_R5","pred":"arg1Of","subj":"EnjuParser_T6","obj":"EnjuParser_T5"},{"id":"EnjuParser_R6","pred":"arg1Of","subj":"EnjuParser_T1","obj":"EnjuParser_T7"},{"id":"EnjuParser_R7","pred":"arg2Of","subj":"EnjuParser_T8","obj":"EnjuParser_T7"},{"id":"EnjuParser_R8","pred":"arg1Of","subj":"EnjuParser_T8","obj":"EnjuParser_T9"},{"id":"EnjuParser_R9","pred":"arg2Of","subj":"EnjuParser_T10","obj":"EnjuParser_T9"},{"id":"EnjuParser_R10","pred":"arg1Of","subj":"EnjuParser_T11","obj":"EnjuParser_T12"},{"id":"EnjuParser_R11","pred":"arg1Of","subj":"EnjuParser_T13","obj":"EnjuParser_T14"},{"id":"EnjuParser_R12","pred":"arg2Of","subj":"EnjuParser_T15","obj":"EnjuParser_T14"},{"id":"EnjuParser_R13","pred":"arg1Of","subj":"EnjuParser_T13","obj":"EnjuParser_T15"},{"id":"EnjuParser_R14","pred":"arg2Of","subj":"EnjuParser_T38","obj":"EnjuParser_T15"},{"id":"EnjuParser_R15","pred":"arg1Of","subj":"EnjuParser_T38","obj":"EnjuParser_T16"},{"id":"EnjuParser_R16","pred":"arg1Of","subj":"EnjuParser_T19","obj":"EnjuParser_T17"},{"id":"EnjuParser_R17","pred":"arg1Of","subj":"EnjuParser_T19","obj":"EnjuParser_T18"},{"id":"EnjuParser_R18","pred":"arg1Of","subj":"EnjuParser_T19","obj":"EnjuParser_T20"},{"id":"EnjuParser_R19","pred":"arg2Of","subj":"EnjuParser_T21","obj":"EnjuParser_T20"},{"id":"EnjuParser_R20","pred":"arg3Of","subj":"EnjuParser_T23","obj":"EnjuParser_T20"},{"id":"EnjuParser_R21","pred":"arg1Of","subj":"EnjuParser_T23","obj":"EnjuParser_T22"},{"id":"EnjuParser_R22","pred":"arg1Of","subj":"EnjuParser_T21","obj":"EnjuParser_T23"},{"id":"EnjuParser_R23","pred":"arg1Of","subj":"EnjuParser_T25","obj":"EnjuParser_T24"},{"id":"EnjuParser_R24","pred":"modOf","subj":"EnjuParser_T20","obj":"EnjuParser_T24"},{"id":"EnjuParser_R25","pred":"arg2Of","subj":"EnjuParser_T33","obj":"EnjuParser_T25"},{"id":"EnjuParser_R26","pred":"arg1Of","subj":"EnjuParser_T33","obj":"EnjuParser_T26"},{"id":"EnjuParser_R27","pred":"arg1Of","subj":"EnjuParser_T29","obj":"EnjuParser_T27"},{"id":"EnjuParser_R28","pred":"arg1Of","subj":"EnjuParser_T29","obj":"EnjuParser_T28"},{"id":"EnjuParser_R29","pred":"arg1Of","subj":"EnjuParser_T33","obj":"EnjuParser_T29"},{"id":"EnjuParser_R30","pred":"arg1Of","subj":"EnjuParser_T29","obj":"EnjuParser_T30"},{"id":"EnjuParser_R31","pred":"arg2Of","subj":"EnjuParser_T31","obj":"EnjuParser_T30"},{"id":"EnjuParser_R32","pred":"arg3Of","subj":"EnjuParser_T32","obj":"EnjuParser_T30"},{"id":"EnjuParser_R33","pred":"arg1Of","subj":"EnjuParser_T20","obj":"EnjuParser_T34"},{"id":"EnjuParser_R34","pred":"arg2Of","subj":"EnjuParser_T35","obj":"EnjuParser_T34"},{"id":"EnjuParser_R35","pred":"arg3Of","subj":"EnjuParser_T36","obj":"EnjuParser_T34"},{"id":"EnjuParser_R36","pred":"arg1Of","subj":"EnjuParser_T38","obj":"EnjuParser_T37"},{"id":"EnjuParser_R37","pred":"arg1Of","subj":"EnjuParser_T20","obj":"EnjuParser_T38"},{"id":"EnjuParser_R38","pred":"arg2Of","subj":"EnjuParser_T39","obj":"EnjuParser_T38"},{"id":"EnjuParser_R39","pred":"arg1Of","subj":"EnjuParser_T19","obj":"EnjuParser_T39"},{"id":"EnjuParser_R40","pred":"arg2Of","subj":"EnjuParser_T41","obj":"EnjuParser_T39"},{"id":"EnjuParser_R41","pred":"arg1Of","subj":"EnjuParser_T41","obj":"EnjuParser_T40"},{"id":"EnjuParser_R42","pred":"arg1Of","subj":"EnjuParser_T43","obj":"EnjuParser_T42"},{"id":"EnjuParser_R43","pred":"arg1Of","subj":"EnjuParser_T43","obj":"EnjuParser_T44"},{"id":"EnjuParser_R44","pred":"arg2Of","subj":"EnjuParser_T46","obj":"EnjuParser_T44"},{"id":"EnjuParser_R45","pred":"arg1Of","subj":"EnjuParser_T46","obj":"EnjuParser_T45"},{"id":"EnjuParser_R46","pred":"arg1Of","subj":"EnjuParser_T43","obj":"EnjuParser_T47"},{"id":"EnjuParser_R47","pred":"arg2Of","subj":"EnjuParser_T49","obj":"EnjuParser_T47"},{"id":"EnjuParser_R48","pred":"arg1Of","subj":"EnjuParser_T49","obj":"EnjuParser_T48"},{"id":"EnjuParser_R49","pred":"arg2Of","subj":"EnjuParser_T51","obj":"EnjuParser_T49"},{"id":"EnjuParser_R50","pred":"arg1Of","subj":"EnjuParser_T51","obj":"EnjuParser_T50"},{"id":"EnjuParser_R51","pred":"arg1Of","subj":"EnjuParser_T51","obj":"EnjuParser_T52"},{"id":"EnjuParser_R52","pred":"arg2Of","subj":"EnjuParser_T55","obj":"EnjuParser_T52"},{"id":"EnjuParser_R53","pred":"arg1Of","subj":"EnjuParser_T55","obj":"EnjuParser_T53"},{"id":"EnjuParser_R54","pred":"arg1Of","subj":"EnjuParser_T55","obj":"EnjuParser_T54"},{"id":"EnjuParser_R55","pred":"arg1Of","subj":"EnjuParser_T51","obj":"EnjuParser_T56"},{"id":"EnjuParser_R56","pred":"arg2Of","subj":"EnjuParser_T58","obj":"EnjuParser_T56"},{"id":"EnjuParser_R57","pred":"arg1Of","subj":"EnjuParser_T58","obj":"EnjuParser_T57"},{"id":"EnjuParser_R58","pred":"arg1Of","subj":"EnjuParser_T58","obj":"EnjuParser_T59"},{"id":"EnjuParser_R59","pred":"arg2Of","subj":"EnjuParser_T60","obj":"EnjuParser_T59"},{"id":"EnjuParser_R60","pred":"arg1Of","subj":"EnjuParser_T61","obj":"EnjuParser_T62"},{"id":"EnjuParser_R61","pred":"arg1Of","subj":"EnjuParser_T64","obj":"EnjuParser_T63"},{"id":"EnjuParser_R62","pred":"arg1Of","subj":"EnjuParser_T64","obj":"EnjuParser_T65"},{"id":"EnjuParser_R63","pred":"arg2Of","subj":"EnjuParser_T67","obj":"EnjuParser_T65"},{"id":"EnjuParser_R64","pred":"arg1Of","subj":"EnjuParser_T67","obj":"EnjuParser_T66"},{"id":"EnjuParser_R65","pred":"arg1Of","subj":"EnjuParser_T67","obj":"EnjuParser_T68"},{"id":"EnjuParser_R66","pred":"arg1Of","subj":"EnjuParser_T67","obj":"EnjuParser_T69"},{"id":"EnjuParser_R67","pred":"arg2Of","subj":"EnjuParser_T71","obj":"EnjuParser_T69"},{"id":"EnjuParser_R68","pred":"arg1Of","subj":"EnjuParser_T71","obj":"EnjuParser_T70"},{"id":"EnjuParser_R69","pred":"arg1Of","subj":"EnjuParser_T71","obj":"EnjuParser_T72"},{"id":"EnjuParser_R70","pred":"arg2Of","subj":"EnjuParser_T75","obj":"EnjuParser_T72"},{"id":"EnjuParser_R71","pred":"arg1Of","subj":"EnjuParser_T75","obj":"EnjuParser_T73"},{"id":"EnjuParser_R72","pred":"arg1Of","subj":"EnjuParser_T75","obj":"EnjuParser_T74"},{"id":"EnjuParser_R73","pred":"arg1Of","subj":"EnjuParser_T69","obj":"EnjuParser_T76"},{"id":"EnjuParser_R74","pred":"arg2Of","subj":"EnjuParser_T77","obj":"EnjuParser_T76"},{"id":"EnjuParser_R75","pred":"arg1Of","subj":"EnjuParser_T69","obj":"EnjuParser_T78"},{"id":"EnjuParser_R76","pred":"arg2Of","subj":"EnjuParser_T79","obj":"EnjuParser_T78"},{"id":"EnjuParser_R77","pred":"arg1Of","subj":"EnjuParser_T67","obj":"EnjuParser_T79"},{"id":"EnjuParser_R78","pred":"arg2Of","subj":"EnjuParser_T81","obj":"EnjuParser_T79"},{"id":"EnjuParser_R79","pred":"arg1Of","subj":"EnjuParser_T81","obj":"EnjuParser_T80"},{"id":"EnjuParser_R80","pred":"arg1Of","subj":"EnjuParser_T81","obj":"EnjuParser_T82"},{"id":"EnjuParser_R81","pred":"arg2Of","subj":"EnjuParser_T84","obj":"EnjuParser_T82"},{"id":"EnjuParser_R82","pred":"arg1Of","subj":"EnjuParser_T84","obj":"EnjuParser_T83"},{"id":"EnjuParser_R83","pred":"arg1Of","subj":"EnjuParser_T79","obj":"EnjuParser_T85"},{"id":"EnjuParser_R84","pred":"arg2Of","subj":"EnjuParser_T89","obj":"EnjuParser_T85"},{"id":"EnjuParser_R85","pred":"arg1Of","subj":"EnjuParser_T89","obj":"EnjuParser_T86"},{"id":"EnjuParser_R86","pred":"arg1Of","subj":"EnjuParser_T86","obj":"EnjuParser_T87"},{"id":"EnjuParser_R87","pred":"arg2Of","subj":"EnjuParser_T88","obj":"EnjuParser_T87"},{"id":"EnjuParser_R88","pred":"arg1Of","subj":"EnjuParser_T89","obj":"EnjuParser_T88"},{"id":"EnjuParser_R89","pred":"arg1Of","subj":"EnjuParser_T64","obj":"EnjuParser_T90"},{"id":"EnjuParser_R90","pred":"arg2Of","subj":"EnjuParser_T91","obj":"EnjuParser_T90"},{"id":"EnjuParser_R91","pred":"modOf","subj":"EnjuParser_T61","obj":"EnjuParser_T90"},{"id":"EnjuParser_R92","pred":"arg2Of","subj":"EnjuParser_T64","obj":"EnjuParser_T91"},{"id":"EnjuParser_R93","pred":"arg1Of","subj":"EnjuParser_T92","obj":"EnjuParser_T93"},{"id":"EnjuParser_R94","pred":"arg2Of","subj":"EnjuParser_T94","obj":"EnjuParser_T93"},{"id":"EnjuParser_R95","pred":"arg1Of","subj":"EnjuParser_T93","obj":"EnjuParser_T95"},{"id":"EnjuParser_R96","pred":"arg2Of","subj":"EnjuParser_T96","obj":"EnjuParser_T95"},{"id":"EnjuParser_R97","pred":"arg2Of","subj":"EnjuParser_T93","obj":"EnjuParser_T96"},{"id":"EnjuParser_R98","pred":"arg1Of","subj":"EnjuParser_T96","obj":"EnjuParser_T97"},{"id":"EnjuParser_R99","pred":"arg2Of","subj":"EnjuParser_T99","obj":"EnjuParser_T97"},{"id":"EnjuParser_R100","pred":"arg1Of","subj":"EnjuParser_T99","obj":"EnjuParser_T98"},{"id":"EnjuParser_R101","pred":"arg1Of","subj":"EnjuParser_T100","obj":"EnjuParser_T101"},{"id":"EnjuParser_R102","pred":"arg1Of","subj":"EnjuParser_T103","obj":"EnjuParser_T102"},{"id":"EnjuParser_R103","pred":"arg1Of","subj":"EnjuParser_T103","obj":"EnjuParser_T104"},{"id":"EnjuParser_R104","pred":"arg2Of","subj":"EnjuParser_T106","obj":"EnjuParser_T104"},{"id":"EnjuParser_R105","pred":"arg1Of","subj":"EnjuParser_T106","obj":"EnjuParser_T105"},{"id":"EnjuParser_R106","pred":"arg1Of","subj":"EnjuParser_T103","obj":"EnjuParser_T107"},{"id":"EnjuParser_R107","pred":"arg2Of","subj":"EnjuParser_T109","obj":"EnjuParser_T107"},{"id":"EnjuParser_R108","pred":"arg1Of","subj":"EnjuParser_T109","obj":"EnjuParser_T108"},{"id":"EnjuParser_R109","pred":"arg1Of","subj":"EnjuParser_T103","obj":"EnjuParser_T110"},{"id":"EnjuParser_R110","pred":"arg2Of","subj":"EnjuParser_T111","obj":"EnjuParser_T110"},{"id":"EnjuParser_R111","pred":"modOf","subj":"EnjuParser_T100","obj":"EnjuParser_T110"},{"id":"EnjuParser_R112","pred":"arg2Of","subj":"EnjuParser_T103","obj":"EnjuParser_T111"},{"id":"EnjuParser_R113","pred":"arg1Of","subj":"EnjuParser_T111","obj":"EnjuParser_T112"},{"id":"EnjuParser_R114","pred":"arg2Of","subj":"EnjuParser_T114","obj":"EnjuParser_T112"},{"id":"EnjuParser_R115","pred":"arg1Of","subj":"EnjuParser_T114","obj":"EnjuParser_T113"},{"id":"EnjuParser_R116","pred":"arg1Of","subj":"EnjuParser_T116","obj":"EnjuParser_T115"},{"id":"EnjuParser_R117","pred":"arg1Of","subj":"EnjuParser_T116","obj":"EnjuParser_T117"},{"id":"EnjuParser_R118","pred":"arg2Of","subj":"EnjuParser_T121","obj":"EnjuParser_T117"},{"id":"EnjuParser_R119","pred":"arg1Of","subj":"EnjuParser_T118","obj":"EnjuParser_T119"},{"id":"EnjuParser_R120","pred":"arg2Of","subj":"EnjuParser_T120","obj":"EnjuParser_T119"},{"id":"EnjuParser_R121","pred":"arg1Of","subj":"EnjuParser_T119","obj":"EnjuParser_T121"},{"id":"EnjuParser_R122","pred":"arg2Of","subj":"EnjuParser_T122","obj":"EnjuParser_T121"},{"id":"EnjuParser_R123","pred":"arg1Of","subj":"EnjuParser_T116","obj":"EnjuParser_T123"},{"id":"EnjuParser_R124","pred":"arg2Of","subj":"EnjuParser_T124","obj":"EnjuParser_T123"},{"id":"EnjuParser_R125","pred":"arg1Of","subj":"EnjuParser_T124","obj":"EnjuParser_T125"},{"id":"EnjuParser_R126","pred":"arg2Of","subj":"EnjuParser_T126","obj":"EnjuParser_T125"},{"id":"EnjuParser_R127","pred":"arg1Of","subj":"EnjuParser_T116","obj":"EnjuParser_T127"},{"id":"EnjuParser_R128","pred":"arg2Of","subj":"EnjuParser_T130","obj":"EnjuParser_T127"},{"id":"EnjuParser_R129","pred":"arg1Of","subj":"EnjuParser_T129","obj":"EnjuParser_T128"},{"id":"EnjuParser_R130","pred":"arg1Of","subj":"EnjuParser_T129","obj":"EnjuParser_T130"},{"id":"EnjuParser_R131","pred":"arg2Of","subj":"EnjuParser_T135","obj":"EnjuParser_T130"},{"id":"EnjuParser_R132","pred":"arg1Of","subj":"EnjuParser_T132","obj":"EnjuParser_T131"},{"id":"EnjuParser_R133","pred":"arg1Of","subj":"EnjuParser_T135","obj":"EnjuParser_T132"},{"id":"EnjuParser_R134","pred":"arg1Of","subj":"EnjuParser_T132","obj":"EnjuParser_T133"},{"id":"EnjuParser_R135","pred":"arg2Of","subj":"EnjuParser_T134","obj":"EnjuParser_T133"},{"id":"EnjuParser_R136","pred":"arg1Of","subj":"EnjuParser_T135","obj":"EnjuParser_T134"},{"id":"EnjuParser_R137","pred":"arg1Of","subj":"EnjuParser_T127","obj":"EnjuParser_T136"},{"id":"EnjuParser_R138","pred":"arg1Of","subj":"EnjuParser_T127","obj":"EnjuParser_T137"},{"id":"EnjuParser_R139","pred":"arg1Of","subj":"EnjuParser_T139","obj":"EnjuParser_T138"},{"id":"EnjuParser_R140","pred":"arg1Of","subj":"EnjuParser_T139","obj":"EnjuParser_T140"},{"id":"EnjuParser_R141","pred":"arg2Of","subj":"EnjuParser_T145","obj":"EnjuParser_T140"},{"id":"EnjuParser_R142","pred":"arg1Of","subj":"EnjuParser_T141","obj":"EnjuParser_T142"},{"id":"EnjuParser_R143","pred":"arg2Of","subj":"EnjuParser_T144","obj":"EnjuParser_T142"},{"id":"EnjuParser_R144","pred":"arg1Of","subj":"EnjuParser_T144","obj":"EnjuParser_T143"},{"id":"EnjuParser_R145","pred":"arg1Of","subj":"EnjuParser_T142","obj":"EnjuParser_T145"},{"id":"EnjuParser_R146","pred":"arg2Of","subj":"EnjuParser_T146","obj":"EnjuParser_T145"},{"id":"EnjuParser_R147","pred":"arg1Of","subj":"EnjuParser_T139","obj":"EnjuParser_T147"},{"id":"EnjuParser_R148","pred":"arg2Of","subj":"EnjuParser_T148","obj":"EnjuParser_T147"},{"id":"EnjuParser_R149","pred":"arg1Of","subj":"EnjuParser_T139","obj":"EnjuParser_T148"},{"id":"EnjuParser_R150","pred":"arg2Of","subj":"EnjuParser_T152","obj":"EnjuParser_T148"},{"id":"EnjuParser_R151","pred":"arg1Of","subj":"EnjuParser_T149","obj":"EnjuParser_T150"},{"id":"EnjuParser_R152","pred":"arg2Of","subj":"EnjuParser_T151","obj":"EnjuParser_T150"},{"id":"EnjuParser_R153","pred":"arg1Of","subj":"EnjuParser_T150","obj":"EnjuParser_T152"},{"id":"EnjuParser_R154","pred":"arg2Of","subj":"EnjuParser_T153","obj":"EnjuParser_T152"},{"id":"EnjuParser_R155","pred":"arg1Of","subj":"EnjuParser_T152","obj":"EnjuParser_T154"},{"id":"EnjuParser_R156","pred":"arg1Of","subj":"EnjuParser_T152","obj":"EnjuParser_T155"},{"id":"EnjuParser_R157","pred":"arg1Of","subj":"EnjuParser_T152","obj":"EnjuParser_T156"},{"id":"EnjuParser_R158","pred":"arg1Of","subj":"EnjuParser_T152","obj":"EnjuParser_T157"},{"id":"EnjuParser_R159","pred":"arg1Of","subj":"EnjuParser_T157","obj":"EnjuParser_T158"},{"id":"EnjuParser_R160","pred":"arg2Of","subj":"EnjuParser_T160","obj":"EnjuParser_T158"},{"id":"EnjuParser_R161","pred":"arg1Of","subj":"EnjuParser_T160","obj":"EnjuParser_T159"},{"id":"EnjuParser_R162","pred":"arg1Of","subj":"EnjuParser_T157","obj":"EnjuParser_T161"},{"id":"EnjuParser_R163","pred":"arg2Of","subj":"EnjuParser_T162","obj":"EnjuParser_T161"},{"id":"EnjuParser_R164","pred":"arg2Of","subj":"EnjuParser_T165","obj":"EnjuParser_T162"},{"id":"EnjuParser_R165","pred":"arg1Of","subj":"EnjuParser_T165","obj":"EnjuParser_T163"},{"id":"EnjuParser_R166","pred":"arg1Of","subj":"EnjuParser_T165","obj":"EnjuParser_T164"},{"id":"EnjuParser_R167","pred":"arg1Of","subj":"EnjuParser_T168","obj":"EnjuParser_T166"},{"id":"EnjuParser_R168","pred":"arg1Of","subj":"EnjuParser_T168","obj":"EnjuParser_T167"},{"id":"EnjuParser_R169","pred":"arg1Of","subj":"EnjuParser_T170","obj":"EnjuParser_T168"},{"id":"EnjuParser_R170","pred":"arg1Of","subj":"EnjuParser_T168","obj":"EnjuParser_T169"},{"id":"EnjuParser_R171","pred":"arg1Of","subj":"EnjuParser_T170","obj":"EnjuParser_T171"},{"id":"EnjuParser_R172","pred":"arg2Of","subj":"EnjuParser_T172","obj":"EnjuParser_T171"},{"id":"EnjuParser_R173","pred":"arg1Of","subj":"EnjuParser_T170","obj":"EnjuParser_T173"},{"id":"EnjuParser_R174","pred":"arg2Of","subj":"EnjuParser_T177","obj":"EnjuParser_T173"},{"id":"EnjuParser_R175","pred":"arg1Of","subj":"EnjuParser_T177","obj":"EnjuParser_T174"},{"id":"EnjuParser_R176","pred":"arg1Of","subj":"EnjuParser_T177","obj":"EnjuParser_T175"},{"id":"EnjuParser_R177","pred":"arg1Of","subj":"EnjuParser_T177","obj":"EnjuParser_T176"},{"id":"EnjuParser_R178","pred":"arg1Of","subj":"EnjuParser_T179","obj":"EnjuParser_T178"},{"id":"EnjuParser_R179","pred":"arg1Of","subj":"EnjuParser_T179","obj":"EnjuParser_T180"},{"id":"EnjuParser_R180","pred":"arg2Of","subj":"EnjuParser_T183","obj":"EnjuParser_T180"},{"id":"EnjuParser_R181","pred":"arg1Of","subj":"EnjuParser_T183","obj":"EnjuParser_T181"},{"id":"EnjuParser_R182","pred":"arg1Of","subj":"EnjuParser_T183","obj":"EnjuParser_T182"},{"id":"EnjuParser_R183","pred":"arg1Of","subj":"EnjuParser_T179","obj":"EnjuParser_T184"},{"id":"EnjuParser_R184","pred":"arg2Of","subj":"EnjuParser_T187","obj":"EnjuParser_T184"},{"id":"EnjuParser_R185","pred":"arg1Of","subj":"EnjuParser_T186","obj":"EnjuParser_T185"},{"id":"EnjuParser_R186","pred":"arg1Of","subj":"EnjuParser_T187","obj":"EnjuParser_T186"},{"id":"EnjuParser_R187","pred":"arg1Of","subj":"EnjuParser_T187","obj":"EnjuParser_T188"},{"id":"EnjuParser_R188","pred":"arg1Of","subj":"EnjuParser_T188","obj":"EnjuParser_T189"},{"id":"EnjuParser_R189","pred":"arg2Of","subj":"EnjuParser_T191","obj":"EnjuParser_T189"},{"id":"EnjuParser_R190","pred":"arg1Of","subj":"EnjuParser_T191","obj":"EnjuParser_T190"},{"id":"EnjuParser_R191","pred":"arg1Of","subj":"EnjuParser_T188","obj":"EnjuParser_T192"},{"id":"EnjuParser_R192","pred":"arg2Of","subj":"EnjuParser_T193","obj":"EnjuParser_T192"},{"id":"EnjuParser_R193","pred":"arg2Of","subj":"EnjuParser_T196","obj":"EnjuParser_T193"},{"id":"EnjuParser_R194","pred":"arg1Of","subj":"EnjuParser_T196","obj":"EnjuParser_T194"},{"id":"EnjuParser_R195","pred":"arg1Of","subj":"EnjuParser_T196","obj":"EnjuParser_T195"},{"id":"EnjuParser_R196","pred":"arg1Of","subj":"EnjuParser_T197","obj":"EnjuParser_T198"},{"id":"EnjuParser_R197","pred":"arg1Of","subj":"EnjuParser_T199","obj":"EnjuParser_T200"},{"id":"EnjuParser_R198","pred":"arg2Of","subj":"EnjuParser_T204","obj":"EnjuParser_T200"},{"id":"EnjuParser_R199","pred":"arg1Of","subj":"EnjuParser_T203","obj":"EnjuParser_T201"},{"id":"EnjuParser_R200","pred":"arg1Of","subj":"EnjuParser_T203","obj":"EnjuParser_T202"},{"id":"EnjuParser_R201","pred":"arg1Of","subj":"EnjuParser_T204","obj":"EnjuParser_T203"},{"id":"EnjuParser_R202","pred":"arg1Of","subj":"EnjuParser_T199","obj":"EnjuParser_T205"},{"id":"EnjuParser_R203","pred":"arg2Of","subj":"EnjuParser_T206","obj":"EnjuParser_T205"},{"id":"EnjuParser_R204","pred":"arg1Of","subj":"EnjuParser_T199","obj":"EnjuParser_T206"},{"id":"EnjuParser_R205","pred":"arg2Of","subj":"EnjuParser_T209","obj":"EnjuParser_T206"},{"id":"EnjuParser_R206","pred":"arg1Of","subj":"EnjuParser_T209","obj":"EnjuParser_T207"},{"id":"EnjuParser_R207","pred":"arg1Of","subj":"EnjuParser_T209","obj":"EnjuParser_T208"},{"id":"EnjuParser_R208","pred":"arg1Of","subj":"EnjuParser_T209","obj":"EnjuParser_T210"},{"id":"EnjuParser_R209","pred":"arg2Of","subj":"EnjuParser_T211","obj":"EnjuParser_T210"},{"id":"EnjuParser_R210","pred":"arg1Of","subj":"EnjuParser_T211","obj":"EnjuParser_T212"},{"id":"EnjuParser_R211","pred":"arg2Of","subj":"EnjuParser_T215","obj":"EnjuParser_T212"},{"id":"EnjuParser_R212","pred":"arg1Of","subj":"EnjuParser_T215","obj":"EnjuParser_T213"},{"id":"EnjuParser_R213","pred":"arg1Of","subj":"EnjuParser_T215","obj":"EnjuParser_T214"},{"id":"EnjuParser_R214","pred":"arg1Of","subj":"EnjuParser_T206","obj":"EnjuParser_T216"},{"id":"EnjuParser_R215","pred":"arg2Of","subj":"EnjuParser_T222","obj":"EnjuParser_T216"},{"id":"EnjuParser_R216","pred":"arg1Of","subj":"EnjuParser_T218","obj":"EnjuParser_T217"},{"id":"EnjuParser_R217","pred":"arg1Of","subj":"EnjuParser_T218","obj":"EnjuParser_T219"},{"id":"EnjuParser_R218","pred":"arg2Of","subj":"EnjuParser_T222","obj":"EnjuParser_T219"},{"id":"EnjuParser_R219","pred":"arg1Of","subj":"EnjuParser_T222","obj":"EnjuParser_T220"},{"id":"EnjuParser_R220","pred":"arg1Of","subj":"EnjuParser_T222","obj":"EnjuParser_T221"},{"id":"EnjuParser_R221","pred":"arg1Of","subj":"EnjuParser_T218","obj":"EnjuParser_T222"},{"id":"EnjuParser_R222","pred":"arg2Of","subj":"EnjuParser_T224","obj":"EnjuParser_T222"},{"id":"EnjuParser_R223","pred":"arg1Of","subj":"EnjuParser_T224","obj":"EnjuParser_T223"},{"id":"EnjuParser_R224","pred":"arg1Of","subj":"EnjuParser_T224","obj":"EnjuParser_T225"},{"id":"EnjuParser_R225","pred":"arg2Of","subj":"EnjuParser_T227","obj":"EnjuParser_T225"},{"id":"EnjuParser_R226","pred":"arg1Of","subj":"EnjuParser_T227","obj":"EnjuParser_T226"},{"id":"EnjuParser_R227","pred":"arg1Of","subj":"EnjuParser_T239","obj":"EnjuParser_T228"},{"id":"EnjuParser_R228","pred":"arg2Of","subj":"EnjuParser_T231","obj":"EnjuParser_T228"},{"id":"EnjuParser_R229","pred":"arg1Of","subj":"EnjuParser_T231","obj":"EnjuParser_T229"},{"id":"EnjuParser_R230","pred":"arg1Of","subj":"EnjuParser_T231","obj":"EnjuParser_T230"},{"id":"EnjuParser_R231","pred":"arg1Of","subj":"EnjuParser_T239","obj":"EnjuParser_T232"},{"id":"EnjuParser_R232","pred":"arg1Of","subj":"EnjuParser_T233","obj":"EnjuParser_T234"},{"id":"EnjuParser_R233","pred":"arg2Of","subj":"EnjuParser_T237","obj":"EnjuParser_T236"},{"id":"EnjuParser_R234","pred":"arg1Of","subj":"EnjuParser_T239","obj":"EnjuParser_T238"},{"id":"EnjuParser_R235","pred":"arg1Of","subj":"EnjuParser_T241","obj":"EnjuParser_T239"},{"id":"EnjuParser_R236","pred":"arg1Of","subj":"EnjuParser_T241","obj":"EnjuParser_T240"},{"id":"EnjuParser_R237","pred":"arg1Of","subj":"EnjuParser_T241","obj":"EnjuParser_T242"},{"id":"EnjuParser_R238","pred":"arg2Of","subj":"EnjuParser_T244","obj":"EnjuParser_T242"},{"id":"EnjuParser_R239","pred":"arg1Of","subj":"EnjuParser_T244","obj":"EnjuParser_T243"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-ArguminSci","denotations":[{"id":"T1","span":{"begin":0,"end":80},"obj":"DRI_Background"},{"id":"T2","span":{"begin":81,"end":286},"obj":"DRI_Background"},{"id":"T3","span":{"begin":287,"end":414},"obj":"DRI_Challenge"},{"id":"T4","span":{"begin":415,"end":645},"obj":"DRI_Background"},{"id":"T5","span":{"begin":646,"end":699},"obj":"DRI_Background"},{"id":"T6","span":{"begin":783,"end":927},"obj":"DRI_Background"},{"id":"T7","span":{"begin":928,"end":1134},"obj":"DRI_Background"},{"id":"T8","span":{"begin":1135,"end":1206},"obj":"DRI_Background"},{"id":"T9","span":{"begin":1207,"end":1336},"obj":"DRI_Outcome"},{"id":"T10","span":{"begin":1337,"end":1546},"obj":"DRI_Challenge"},{"id":"T11","span":{"begin":1547,"end":1623},"obj":"DRI_Approach"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-OGER","denotations":[{"id":"T1","span":{"begin":40,"end":49},"obj":"GO:0008152"},{"id":"T2","span":{"begin":135,"end":144},"obj":"GO:0008152"},{"id":"T3","span":{"begin":362,"end":371},"obj":"GO:0008152"},{"id":"T4","span":{"begin":509,"end":518},"obj":"GO:0008152"},{"id":"T5","span":{"begin":1387,"end":1396},"obj":"GO:0008152"},{"id":"T1","span":{"begin":218,"end":223},"obj":"GO:0019012"},{"id":"T1","span":{"begin":426,"end":430},"obj":"PR:000023208"},{"id":"T1","span":{"begin":1410,"end":1414},"obj":"UBERON:0001456"},{"id":"T2","span":{"begin":1560,"end":1564},"obj":"UBERON:0002398"},{"id":"T3","span":{"begin":1617,"end":1622},"obj":"UBERON:0000948"}],"namespaces":[{"prefix":"PR","uri":"http://purl.obolibrary.org/obo/PR_"},{"prefix":"UBERON","uri":"http://purl.obolibrary.org/obo/UBERON_"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PubTatorCentral","denotations":[{"id":"T1","span":{"begin":25,"end":58},"obj":"Disease:MESH:D024821"},{"id":"T2","span":{"begin":120,"end":163},"obj":"Disease:MESH:D024821"},{"id":"T3","span":{"begin":164,"end":172},"obj":"Species:9606"},{"id":"T4","span":{"begin":276,"end":285},"obj":"Disease:MESH:D007239"},{"id":"T5","span":{"begin":347,"end":380},"obj":"Disease:MESH:D024821"},{"id":"T6","span":{"begin":494,"end":527},"obj":"Disease:MESH:D024821"},{"id":"T7","span":{"begin":622,"end":630},"obj":"Species:9606"},{"id":"T8","span":{"begin":742,"end":750},"obj":"Species:9606"},{"id":"T9","span":{"begin":802,"end":814},"obj":"Disease:MESH:D006973"},{"id":"T10","span":{"begin":816,"end":846},"obj":"Disease:MESH:D004938"},{"id":"T11","span":{"begin":851,"end":859},"obj":"Disease:MESH:D003920"},{"id":"T12","span":{"begin":863,"end":871},"obj":"Species:9606"},{"id":"T13","span":{"begin":946,"end":958},"obj":"Disease:MESH:D006973"},{"id":"T14","span":{"begin":960,"end":991},"obj":"Disease:MESH:D004938"},{"id":"T15","span":{"begin":996,"end":1004},"obj":"Disease:MESH:D003920"},{"id":"T16","span":{"begin":1149,"end":1157},"obj":"Species:9606"},{"id":"T17","span":{"begin":1191,"end":1205},"obj":"Disease:MESH:D006331"},{"id":"T18","span":{"begin":1230,"end":1244},"obj":"Disease:MESH:D006331"},{"id":"T19","span":{"begin":1285,"end":1293},"obj":"Species:9606"},{"id":"T20","span":{"begin":1327,"end":1335},"obj":"Species:9606"},{"id":"T21","span":{"begin":1349,"end":1357},"obj":"Species:9606"},{"id":"T22","span":{"begin":1372,"end":1405},"obj":"Disease:MESH:D024821"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-sentences-v1","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":80},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":81,"end":92},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":93,"end":286},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":287,"end":414},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":415,"end":423},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":424,"end":645},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":646,"end":699},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":700,"end":708},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":709,"end":782},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":783,"end":927},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":928,"end":1134},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":1135,"end":1206},"obj":"Sentence"},{"id":"TextSentencer_T13","span":{"begin":1207,"end":1336},"obj":"Sentence"},{"id":"TextSentencer_T14","span":{"begin":1337,"end":1348},"obj":"Sentence"},{"id":"TextSentencer_T15","span":{"begin":1349,"end":1546},"obj":"Sentence"},{"id":"TextSentencer_T16","span":{"begin":1547,"end":1623},"obj":"Sentence"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-TimeML","denotations":[{"id":"tok1","span":{"begin":0,"end":10},"obj":"NNP"},{"id":"tok2","span":{"begin":11,"end":14},"obj":"CC"},{"id":"tok3","span":{"begin":15,"end":21},"obj":"NN"},{"id":"tok4","span":{"begin":22,"end":24},"obj":"IN"},{"id":"tok5","span":{"begin":25,"end":39},"obj":"JJ"},{"id":"tok6","span":{"begin":40,"end":49},"obj":"JJ"},{"id":"tok7","span":{"begin":50,"end":58},"obj":"NNS"},{"id":"tok8","span":{"begin":59,"end":61},"obj":"IN"},{"id":"tok9","span":{"begin":62,"end":68},"obj":"NNP"},{"id":"tok10","span":{"begin":68,"end":70},"obj":"CD"},{"id":"tok11","span":{"begin":71,"end":73},"obj":"IN"},{"id":"tok12","span":{"begin":74,"end":79},"obj":"NNP"},{"id":"tok13","span":{"begin":79,"end":80},"obj":"."},{"id":"tok14","span":{"begin":81,"end":91},"obj":"NNP"},{"id":"tok15","span":{"begin":91,"end":92},"obj":":"},{"id":"tok16","span":{"begin":93,"end":100},"obj":"NNPS"},{"id":"tok17","span":{"begin":101,"end":105},"obj":"VBP"},{"id":"tok18","span":{"begin":106,"end":114},"obj":"VBN"},{"id":"tok19","span":{"begin":115,"end":119},"obj":"IN"},{"id":"tok20","span":{"begin":120,"end":134},"obj":"JJ"},{"id":"tok21","span":{"begin":135,"end":144},"obj":"JJ"},{"id":"tok22","span":{"begin":145,"end":158},"obj":"NNS"},{"id":"tok23","span":{"begin":159,"end":163},"obj":"VBD"},{"id":"tok24","span":{"begin":164,"end":172},"obj":"NNS"},{"id":"tok25","span":{"begin":173,"end":177},"obj":"RBR"},{"id":"tok26","span":{"begin":178,"end":189},"obj":"JJ"},{"id":"tok27","span":{"begin":190,"end":192},"obj":"TO"},{"id":"tok28","span":{"begin":193,"end":199},"obj":"VB"},{"id":"tok29","span":{"begin":200,"end":204},"obj":"CD"},{"id":"tok30","span":{"begin":205,"end":210},"obj":"NN"},{"id":"tok31","span":{"begin":211,"end":217},"obj":"NN"},{"id":"tok32","span":{"begin":218,"end":223},"obj":"NN"},{"id":"tok33","span":{"begin":224,"end":225},"obj":"("},{"id":"tok34","span":{"begin":225,"end":229},"obj":"CD"},{"id":"tok35","span":{"begin":229,"end":230},"obj":":"},{"id":"tok36","span":{"begin":230,"end":234},"obj":"NN"},{"id":"tok37","span":{"begin":234,"end":235},"obj":")"},{"id":"tok38","span":{"begin":236,"end":243},"obj":"NN"},{"id":"tok39","span":{"begin":244,"end":245},"obj":"("},{"id":"tok40","span":{"begin":245,"end":251},"obj":"NNP"},{"id":"tok41","span":{"begin":251,"end":253},"obj":"CD"},{"id":"tok42","span":{"begin":253,"end":254},"obj":")"},{"id":"tok43","span":{"begin":254,"end":255},"obj":","},{"id":"tok44","span":{"begin":256,"end":259},"obj":"CC"},{"id":"tok45","span":{"begin":260,"end":271},"obj":"VBD"},{"id":"tok46","span":{"begin":272,"end":275},"obj":"DT"},{"id":"tok47","span":{"begin":276,"end":285},"obj":"NN"},{"id":"tok48","span":{"begin":285,"end":286},"obj":"."},{"id":"tok49","span":{"begin":287,"end":290},"obj":"DT"},{"id":"tok50","span":{"begin":291,"end":294},"obj":"NN"},{"id":"tok51","span":{"begin":295,"end":297},"obj":"IN"},{"id":"tok52","span":{"begin":298,"end":302},"obj":"DT"},{"id":"tok53","span":{"begin":303,"end":311},"obj":"NN"},{"id":"tok54","span":{"begin":312,"end":314},"obj":"VBZ"},{"id":"tok55","span":{"begin":315,"end":317},"obj":"TO"},{"id":"tok56","span":{"begin":318,"end":327},"obj":"VB"},{"id":"tok57","span":{"begin":328,"end":331},"obj":"DT"},{"id":"tok58","span":{"begin":332,"end":343},"obj":"NN"},{"id":"tok59","span":{"begin":344,"end":346},"obj":"IN"},{"id":"tok60","span":{"begin":347,"end":361},"obj":"JJ"},{"id":"tok61","span":{"begin":362,"end":371},"obj":"JJ"},{"id":"tok62","span":{"begin":372,"end":380},"obj":"NNS"},{"id":"tok63","span":{"begin":381,"end":385},"obj":"IN"},{"id":"tok64","span":{"begin":386,"end":389},"obj":"DT"},{"id":"tok65","span":{"begin":390,"end":401},"obj":"NN"},{"id":"tok66","span":{"begin":402,"end":404},"obj":"IN"},{"id":"tok67","span":{"begin":405,"end":411},"obj":"NNP"},{"id":"tok68","span":{"begin":411,"end":413},"obj":"CD"},{"id":"tok69","span":{"begin":413,"end":414},"obj":"."},{"id":"tok70","span":{"begin":415,"end":422},"obj":"NNP"},{"id":"tok71","span":{"begin":422,"end":423},"obj":":"},{"id":"tok72","span":{"begin":424,"end":425},"obj":"DT"},{"id":"tok73","span":{"begin":426,"end":439},"obj":"JJ"},{"id":"tok74","span":{"begin":440,"end":442},"obj":"IN"},{"id":"tok75","span":{"begin":443,"end":451},"obj":"JJ"},{"id":"tok76","span":{"begin":452,"end":459},"obj":"NNS"},{"id":"tok77","span":{"begin":460,"end":464},"obj":"WDT"},{"id":"tok78","span":{"begin":465,"end":475},"obj":"VBD"},{"id":"tok79","span":{"begin":476,"end":479},"obj":"DT"},{"id":"tok80","span":{"begin":480,"end":490},"obj":"NN"},{"id":"tok81","span":{"begin":491,"end":493},"obj":"IN"},{"id":"tok82","span":{"begin":494,"end":508},"obj":"JJ"},{"id":"tok83","span":{"begin":509,"end":518},"obj":"JJ"},{"id":"tok84","span":{"begin":519,"end":527},"obj":"NNS"},{"id":"tok85","span":{"begin":528,"end":530},"obj":"IN"},{"id":"tok86","span":{"begin":531,"end":537},"obj":"NNP"},{"id":"tok87","span":{"begin":537,"end":539},"obj":"CD"},{"id":"tok88","span":{"begin":540,"end":543},"obj":"CC"},{"id":"tok89","span":{"begin":544,"end":552},"obj":"VBD"},{"id":"tok90","span":{"begin":553,"end":556},"obj":"DT"},{"id":"tok91","span":{"begin":557,"end":567},"obj":"NNS"},{"id":"tok92","span":{"begin":568,"end":570},"obj":"IN"},{"id":"tok93","span":{"begin":571,"end":574},"obj":"DT"},{"id":"tok94","span":{"begin":575,"end":588},"obj":"NNS"},{"id":"tok95","span":{"begin":589,"end":591},"obj":"IN"},{"id":"tok96","span":{"begin":592,"end":595},"obj":"NNP"},{"id":"tok97","span":{"begin":595,"end":596},"obj":"NN"},{"id":"tok98","span":{"begin":596,"end":602},"obj":"JJ"},{"id":"tok99","span":{"begin":603,"end":606},"obj":"CC"},{"id":"tok100","span":{"begin":607,"end":611},"obj":"NN"},{"id":"tok101","span":{"begin":611,"end":614},"obj":"NNP"},{"id":"tok102","span":{"begin":614,"end":615},"obj":"NN"},{"id":"tok103","span":{"begin":615,"end":621},"obj":"JJ"},{"id":"tok104","span":{"begin":622,"end":630},"obj":"NNS"},{"id":"tok105","span":{"begin":631,"end":634},"obj":"VBD"},{"id":"tok106","span":{"begin":635,"end":644},"obj":"VBN"},{"id":"tok107","span":{"begin":644,"end":645},"obj":"."},{"id":"tok108","span":{"begin":646,"end":652},"obj":"NNP"},{"id":"tok109","span":{"begin":653,"end":656},"obj":"CC"},{"id":"tok110","span":{"begin":657,"end":663},"obj":"NNP"},{"id":"tok111","span":{"begin":664,"end":668},"obj":"VBD"},{"id":"tok112","span":{"begin":669,"end":677},"obj":"VBD"},{"id":"tok113","span":{"begin":678,"end":681},"obj":"IN"},{"id":"tok114","span":{"begin":682,"end":690},"obj":"JJ"},{"id":"tok115","span":{"begin":691,"end":698},"obj":"NNS"},{"id":"tok116","span":{"begin":698,"end":699},"obj":"."},{"id":"tok117","span":{"begin":700,"end":707},"obj":"NNP"},{"id":"tok118","span":{"begin":707,"end":708},"obj":":"},{"id":"tok119","span":{"begin":709,"end":710},"obj":"DT"},{"id":"tok120","span":{"begin":711,"end":716},"obj":"NN"},{"id":"tok121","span":{"begin":717,"end":719},"obj":"IN"},{"id":"tok122","span":{"begin":720,"end":723},"obj":"CD"},{"id":"tok123","span":{"begin":724,"end":731},"obj":"NNS"},{"id":"tok124","span":{"begin":732,"end":736},"obj":"IN"},{"id":"tok125","span":{"begin":737,"end":741},"obj":"CD"},{"id":"tok126","span":{"begin":742,"end":750},"obj":"NNS"},{"id":"tok127","span":{"begin":751,"end":755},"obj":"VBD"},{"id":"tok128","span":{"begin":756,"end":764},"obj":"VBN"},{"id":"tok129","span":{"begin":765,"end":767},"obj":"IN"},{"id":"tok130","span":{"begin":768,"end":772},"obj":"DT"},{"id":"tok131","span":{"begin":773,"end":781},"obj":"NN"},{"id":"tok132","span":{"begin":781,"end":782},"obj":"."},{"id":"tok133","span":{"begin":783,"end":786},"obj":"DT"},{"id":"tok134","span":{"begin":787,"end":798},"obj":"NNS"},{"id":"tok135","span":{"begin":799,"end":801},"obj":"IN"},{"id":"tok136","span":{"begin":802,"end":814},"obj":"NN"},{"id":"tok137","span":{"begin":814,"end":815},"obj":","},{"id":"tok138","span":{"begin":816,"end":838},"obj":"JJ"},{"id":"tok139","span":{"begin":839,"end":846},"obj":"NN"},{"id":"tok140","span":{"begin":847,"end":850},"obj":"CC"},{"id":"tok141","span":{"begin":851,"end":859},"obj":"NN"},{"id":"tok142","span":{"begin":860,"end":862},"obj":"IN"},{"id":"tok143","span":{"begin":863,"end":871},"obj":"NNS"},{"id":"tok144","span":{"begin":872,"end":876},"obj":"IN"},{"id":"tok145","span":{"begin":877,"end":883},"obj":"NNP"},{"id":"tok146","span":{"begin":883,"end":885},"obj":"CD"},{"id":"tok147","span":{"begin":886,"end":890},"obj":"VBD"},{"id":"tok148","span":{"begin":891,"end":893},"obj":"CD"},{"id":"tok149","span":{"begin":893,"end":894},"obj":"."},{"id":"tok150","span":{"begin":894,"end":895},"obj":"CD"},{"id":"tok151","span":{"begin":895,"end":896},"obj":"NN"},{"id":"tok152","span":{"begin":896,"end":897},"obj":","},{"id":"tok153","span":{"begin":898,"end":900},"obj":"CD"},{"id":"tok154","span":{"begin":900,"end":901},"obj":"."},{"id":"tok155","span":{"begin":901,"end":902},"obj":"CD"},{"id":"tok156","span":{"begin":902,"end":903},"obj":"NN"},{"id":"tok157","span":{"begin":904,"end":907},"obj":"CC"},{"id":"tok158","span":{"begin":908,"end":909},"obj":"CD"},{"id":"tok159","span":{"begin":909,"end":910},"obj":"."},{"id":"tok160","span":{"begin":910,"end":911},"obj":"CD"},{"id":"tok161","span":{"begin":911,"end":912},"obj":"NN"},{"id":"tok162","span":{"begin":912,"end":913},"obj":","},{"id":"tok163","span":{"begin":914,"end":926},"obj":"RB"},{"id":"tok164","span":{"begin":926,"end":927},"obj":"."},{"id":"tok165","span":{"begin":928,"end":931},"obj":"DT"},{"id":"tok166","span":{"begin":932,"end":942},"obj":"NNS"},{"id":"tok167","span":{"begin":943,"end":945},"obj":"IN"},{"id":"tok168","span":{"begin":946,"end":958},"obj":"NN"},{"id":"tok169","span":{"begin":958,"end":959},"obj":","},{"id":"tok170","span":{"begin":960,"end":982},"obj":"JJ"},{"id":"tok171","span":{"begin":983,"end":991},"obj":"NNS"},{"id":"tok172","span":{"begin":992,"end":995},"obj":"CC"},{"id":"tok173","span":{"begin":996,"end":1004},"obj":"NN"},{"id":"tok174","span":{"begin":1005,"end":1009},"obj":"VBD"},{"id":"tok175","span":{"begin":1010,"end":1015},"obj":"IN"},{"id":"tok176","span":{"begin":1016,"end":1024},"obj":"NNS"},{"id":"tok177","span":{"begin":1024,"end":1025},"obj":","},{"id":"tok178","span":{"begin":1026,"end":1036},"obj":"NNS"},{"id":"tok179","span":{"begin":1037,"end":1040},"obj":"CC"},{"id":"tok180","span":{"begin":1041,"end":1049},"obj":"NNS"},{"id":"tok181","span":{"begin":1049,"end":1050},"obj":","},{"id":"tok182","span":{"begin":1051,"end":1063},"obj":"RB"},{"id":"tok183","span":{"begin":1063,"end":1064},"obj":","},{"id":"tok184","span":{"begin":1065,"end":1071},"obj":"JJR"},{"id":"tok185","span":{"begin":1072,"end":1074},"obj":"IN"},{"id":"tok186","span":{"begin":1075,"end":1078},"obj":"NNP"},{"id":"tok187","span":{"begin":1078,"end":1079},"obj":"NN"},{"id":"tok188","span":{"begin":1079,"end":1085},"obj":"JJ"},{"id":"tok189","span":{"begin":1086,"end":1091},"obj":"NNS"},{"id":"tok190","span":{"begin":1092,"end":1096},"obj":"IN"},{"id":"tok191","span":{"begin":1097,"end":1099},"obj":"IN"},{"id":"tok192","span":{"begin":1100,"end":1105},"obj":"PRP$"},{"id":"tok193","span":{"begin":1106,"end":1110},"obj":"NN"},{"id":"tok194","span":{"begin":1110,"end":1113},"obj":"NNP"},{"id":"tok195","span":{"begin":1113,"end":1114},"obj":"NN"},{"id":"tok196","span":{"begin":1114,"end":1120},"obj":"JJ"},{"id":"tok197","span":{"begin":1121,"end":1133},"obj":"NNS"},{"id":"tok198","span":{"begin":1133,"end":1134},"obj":"."},{"id":"tok199","span":{"begin":1135,"end":1137},"obj":"IN"},{"id":"tok200","span":{"begin":1138,"end":1143},"obj":"JJS"},{"id":"tok201","span":{"begin":1144,"end":1145},"obj":"CD"},{"id":"tok202","span":{"begin":1145,"end":1146},"obj":"."},{"id":"tok203","span":{"begin":1146,"end":1147},"obj":"CD"},{"id":"tok204","span":{"begin":1147,"end":1148},"obj":"NN"},{"id":"tok205","span":{"begin":1149,"end":1157},"obj":"NNS"},{"id":"tok206","span":{"begin":1158,"end":1162},"obj":"IN"},{"id":"tok207","span":{"begin":1163,"end":1169},"obj":"NNP"},{"id":"tok208","span":{"begin":1169,"end":1171},"obj":"CD"},{"id":"tok209","span":{"begin":1172,"end":1180},"obj":"VBD"},{"id":"tok210","span":{"begin":1181,"end":1184},"obj":"DT"},{"id":"tok211","span":{"begin":1185,"end":1190},"obj":"JJ"},{"id":"tok212","span":{"begin":1191,"end":1198},"obj":"JJ"},{"id":"tok213","span":{"begin":1199,"end":1205},"obj":"NN"},{"id":"tok214","span":{"begin":1205,"end":1206},"obj":"."},{"id":"tok215","span":{"begin":1207,"end":1210},"obj":"DT"},{"id":"tok216","span":{"begin":1211,"end":1220},"obj":"NN"},{"id":"tok217","span":{"begin":1221,"end":1223},"obj":"IN"},{"id":"tok218","span":{"begin":1224,"end":1229},"obj":"JJ"},{"id":"tok219","span":{"begin":1230,"end":1237},"obj":"JJ"},{"id":"tok220","span":{"begin":1238,"end":1244},"obj":"NN"},{"id":"tok221","span":{"begin":1245,"end":1248},"obj":"VBD"},{"id":"tok222","span":{"begin":1249,"end":1254},"obj":"IN"},{"id":"tok223","span":{"begin":1255,"end":1257},"obj":"CD"},{"id":"tok224","span":{"begin":1258,"end":1263},"obj":"NNS"},{"id":"tok225","span":{"begin":1264,"end":1270},"obj":"JJR"},{"id":"tok226","span":{"begin":1271,"end":1273},"obj":"IN"},{"id":"tok227","span":{"begin":1274,"end":1277},"obj":"NNP"},{"id":"tok228","span":{"begin":1277,"end":1278},"obj":"NN"},{"id":"tok229","span":{"begin":1278,"end":1284},"obj":"JJ"},{"id":"tok230","span":{"begin":1285,"end":1293},"obj":"NNS"},{"id":"tok231","span":{"begin":1294,"end":1302},"obj":"VBN"},{"id":"tok232","span":{"begin":1303,"end":1307},"obj":"IN"},{"id":"tok233","span":{"begin":1308,"end":1311},"obj":"DT"},{"id":"tok234","span":{"begin":1312,"end":1316},"obj":"NN"},{"id":"tok235","span":{"begin":1316,"end":1319},"obj":"NNP"},{"id":"tok236","span":{"begin":1319,"end":1320},"obj":"NN"},{"id":"tok237","span":{"begin":1320,"end":1326},"obj":"JJ"},{"id":"tok238","span":{"begin":1327,"end":1335},"obj":"NNS"},{"id":"tok239","span":{"begin":1335,"end":1336},"obj":"."},{"id":"tok240","span":{"begin":1337,"end":1347},"obj":"NNP"},{"id":"tok241","span":{"begin":1347,"end":1348},"obj":":"},{"id":"tok242","span":{"begin":1349,"end":1357},"obj":"NNS"},{"id":"tok243","span":{"begin":1358,"end":1362},"obj":"IN"},{"id":"tok244","span":{"begin":1363,"end":1371},"obj":"JJ"},{"id":"tok245","span":{"begin":1372,"end":1386},"obj":"JJ"},{"id":"tok246","span":{"begin":1387,"end":1396},"obj":"JJ"},{"id":"tok247","span":{"begin":1397,"end":1405},"obj":"NNS"},{"id":"tok248","span":{"begin":1406,"end":1409},"obj":"MD"},{"id":"tok249","span":{"begin":1410,"end":1414},"obj":"VB"},{"id":"tok250","span":{"begin":1415,"end":1416},"obj":"DT"},{"id":"tok251","span":{"begin":1417,"end":1424},"obj":"JJR"},{"id":"tok252","span":{"begin":1425,"end":1429},"obj":"NN"},{"id":"tok253","span":{"begin":1430,"end":1432},"obj":"IN"},{"id":"tok254","span":{"begin":1433,"end":1443},"obj":"VBG"},{"id":"tok255","span":{"begin":1444,"end":1448},"obj":"IN"},{"id":"tok256","span":{"begin":1449,"end":1452},"obj":"DT"},{"id":"tok257","span":{"begin":1453,"end":1459},"obj":"JJ"},{"id":"tok258","span":{"begin":1460,"end":1469},"obj":"NN"},{"id":"tok259","span":{"begin":1470,"end":1473},"obj":"CC"},{"id":"tok260","span":{"begin":1474,"end":1477},"obj":"DT"},{"id":"tok261","span":{"begin":1478,"end":1491},"obj":"NNS"},{"id":"tok262","span":{"begin":1492,"end":1495},"obj":"MD"},{"id":"tok263","span":{"begin":1496,"end":1500},"obj":"RB"},{"id":"tok264","span":{"begin":1501,"end":1508},"obj":"RB"},{"id":"tok265","span":{"begin":1509,"end":1515},"obj":"VB"},{"id":"tok266","span":{"begin":1516,"end":1519},"obj":"DT"},{"id":"tok267","span":{"begin":1520,"end":1529},"obj":"NN"},{"id":"tok268","span":{"begin":1530,"end":1532},"obj":"IN"},{"id":"tok269","span":{"begin":1533,"end":1536},"obj":"DT"},{"id":"tok270","span":{"begin":1537,"end":1543},"obj":"NNP"},{"id":"tok271","span":{"begin":1543,"end":1545},"obj":"CD"},{"id":"tok272","span":{"begin":1545,"end":1546},"obj":"."},{"id":"tok273","span":{"begin":1547,"end":1549},"obj":"IN"},{"id":"tok274","span":{"begin":1550,"end":1553},"obj":"DT"},{"id":"tok275","span":{"begin":1554,"end":1559},"obj":"JJ"},{"id":"tok276","span":{"begin":1560,"end":1564},"obj":"NN"},{"id":"tok277","span":{"begin":1564,"end":1565},"obj":","},{"id":"tok278","span":{"begin":1566,"end":1572},"obj":"NNP"},{"id":"tok279","span":{"begin":1572,"end":1574},"obj":"CD"},{"id":"tok280","span":{"begin":1575,"end":1578},"obj":"MD"},{"id":"tok281","span":{"begin":1578,"end":1579},"obj":","},{"id":"tok282","span":{"begin":1580,"end":1582},"obj":"IN"},{"id":"tok283","span":{"begin":1583,"end":1587},"obj":"VB"},{"id":"tok284","span":{"begin":1587,"end":1588},"obj":","},{"id":"tok285","span":{"begin":1589,"end":1598},"obj":"VBP"},{"id":"tok286","span":{"begin":1599,"end":1602},"obj":"DT"},{"id":"tok287","span":{"begin":1603,"end":1609},"obj":"NN"},{"id":"tok288","span":{"begin":1610,"end":1612},"obj":"TO"},{"id":"tok289","span":{"begin":1613,"end":1616},"obj":"DT"},{"id":"tok290","span":{"begin":1617,"end":1622},"obj":"NN"},{"id":"tok291","span":{"begin":1622,"end":1623},"obj":"."},{"id":"lookup1","span":{"begin":71,"end":73},"obj":"country_code"},{"id":"lookup2","span":{"begin":74,"end":79},"obj":"location"},{"id":"lookup3","span":{"begin":190,"end":192},"obj":"country_code"},{"id":"lookup4","span":{"begin":200,"end":204},"obj":"year"},{"id":"lookup5","span":{"begin":225,"end":229},"obj":"year"},{"id":"lookup6","span":{"begin":298,"end":302},"obj":"time_modifier"},{"id":"lookup7","span":{"begin":312,"end":314},"obj":"country_code"},{"id":"lookup8","span":{"begin":315,"end":317},"obj":"country_code"},{"id":"lookup9","span":{"begin":426,"end":430},"obj":"person_first"},{"id":"lookup10","span":{"begin":528,"end":530},"obj":"country_code"},{"id":"lookup11","span":{"begin":589,"end":591},"obj":"country_code"},{"id":"lookup12","span":{"begin":720,"end":723},"obj":"time"},{"id":"lookup13","span":{"begin":720,"end":723},"obj":"number"},{"id":"lookup14","span":{"begin":765,"end":767},"obj":"country_code"},{"id":"lookup15","span":{"begin":768,"end":772},"obj":"time_modifier"},{"id":"lookup16","span":{"begin":860,"end":862},"obj":"country_code"},{"id":"lookup17","span":{"begin":895,"end":896},"obj":"percent"},{"id":"lookup18","span":{"begin":902,"end":903},"obj":"percent"},{"id":"lookup19","span":{"begin":911,"end":912},"obj":"percent"},{"id":"lookup20","span":{"begin":1072,"end":1074},"obj":"country_code"},{"id":"lookup21","span":{"begin":1097,"end":1099},"obj":"country_code"},{"id":"lookup22","span":{"begin":1147,"end":1148},"obj":"percent"},{"id":"lookup23","span":{"begin":1271,"end":1273},"obj":"country_code"},{"id":"lookup24","span":{"begin":1363,"end":1371},"obj":"time_modifier"},{"id":"lookup25","span":{"begin":1580,"end":1582},"obj":"country_code"},{"id":"lookup26","span":{"begin":1610,"end":1612},"obj":"country_code"},{"id":"event1","span":{"begin":1172,"end":1180},"obj":"OCCURRENCE"},{"id":"event2","span":{"begin":756,"end":764},"obj":"OCCURRENCE"},{"id":"event3","span":{"begin":318,"end":327},"obj":"OCCURRENCE"},{"id":"event4","span":{"begin":1589,"end":1598},"obj":"OCCURRENCE"},{"id":"event5","span":{"begin":1509,"end":1515},"obj":"OCCURRENCE"},{"id":"event6","span":{"begin":260,"end":271},"obj":"OCCURRENCE"},{"id":"event7","span":{"begin":159,"end":163},"obj":"OCCURRENCE"},{"id":"event8","span":{"begin":1410,"end":1414},"obj":"OCCURRENCE"},{"id":"event9","span":{"begin":1433,"end":1443},"obj":"OCCURRENCE"},{"id":"event10","span":{"begin":106,"end":114},"obj":"OCCURRENCE"},{"id":"event11","span":{"begin":193,"end":199},"obj":"OCCURRENCE"},{"id":"event12","span":{"begin":465,"end":475},"obj":"OCCURRENCE"},{"id":"event13","span":{"begin":635,"end":644},"obj":"OCCURRENCE"},{"id":"event14","span":{"begin":669,"end":677},"obj":"OCCURRENCE"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PD-MONDO-v1","denotations":[{"id":"T1","span":{"begin":40,"end":58},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":70},"obj":"Disease"},{"id":"T3","span":{"begin":245,"end":253},"obj":"Disease"},{"id":"T4","span":{"begin":276,"end":285},"obj":"Disease"},{"id":"T5","span":{"begin":362,"end":380},"obj":"Disease"},{"id":"T6","span":{"begin":405,"end":413},"obj":"Disease"},{"id":"T7","span":{"begin":509,"end":527},"obj":"Disease"},{"id":"T8","span":{"begin":531,"end":539},"obj":"Disease"},{"id":"T9","span":{"begin":802,"end":814},"obj":"Disease"},{"id":"T10","span":{"begin":823,"end":846},"obj":"Disease"},{"id":"T11","span":{"begin":851,"end":859},"obj":"Disease"},{"id":"T12","span":{"begin":877,"end":885},"obj":"Disease"},{"id":"T13","span":{"begin":946,"end":958},"obj":"Disease"},{"id":"T14","span":{"begin":967,"end":991},"obj":"Disease"},{"id":"T15","span":{"begin":996,"end":1004},"obj":"Disease"},{"id":"T16","span":{"begin":1163,"end":1171},"obj":"Disease"},{"id":"T17","span":{"begin":1199,"end":1205},"obj":"Disease"},{"id":"T18","span":{"begin":1238,"end":1244},"obj":"Disease"},{"id":"T19","span":{"begin":1387,"end":1405},"obj":"Disease"},{"id":"T20","span":{"begin":1537,"end":1545},"obj":"Disease"},{"id":"T21","span":{"begin":1566,"end":1574},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PD-HP-v1","denotations":[{"id":"T1","span":{"begin":802,"end":814},"obj":"Phenotype"},{"id":"T2","span":{"begin":946,"end":958},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PD-FMA-UBERON-v1","denotations":[{"id":"T1","span":{"begin":1410,"end":1414},"obj":"Body_part"},{"id":"T2","span":{"begin":1560,"end":1564},"obj":"Body_part"},{"id":"T3","span":{"begin":1617,"end":1622},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A90308","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma9712"},{"id":"A75309","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A46012","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":1410,"end":1414},"obj":"Body_part"},{"id":"T2","span":{"begin":1560,"end":1564},"obj":"Body_part"},{"id":"T3","span":{"begin":1617,"end":1622},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma9712"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma7088"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":1410,"end":1414},"obj":"Body_part"},{"id":"T2","span":{"begin":1560,"end":1564},"obj":"Body_part"},{"id":"T3","span":{"begin":1617,"end":1622},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":40,"end":58},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":70},"obj":"Disease"},{"id":"T3","span":{"begin":245,"end":253},"obj":"Disease"},{"id":"T4","span":{"begin":276,"end":285},"obj":"Disease"},{"id":"T5","span":{"begin":362,"end":380},"obj":"Disease"},{"id":"T6","span":{"begin":405,"end":413},"obj":"Disease"},{"id":"T7","span":{"begin":509,"end":527},"obj":"Disease"},{"id":"T8","span":{"begin":531,"end":539},"obj":"Disease"},{"id":"T9","span":{"begin":802,"end":814},"obj":"Disease"},{"id":"T10","span":{"begin":823,"end":846},"obj":"Disease"},{"id":"T11","span":{"begin":851,"end":859},"obj":"Disease"},{"id":"T12","span":{"begin":877,"end":885},"obj":"Disease"},{"id":"T13","span":{"begin":946,"end":958},"obj":"Disease"},{"id":"T14","span":{"begin":967,"end":991},"obj":"Disease"},{"id":"T15","span":{"begin":996,"end":1004},"obj":"Disease"},{"id":"T16","span":{"begin":1163,"end":1171},"obj":"Disease"},{"id":"T17","span":{"begin":1199,"end":1205},"obj":"Disease"},{"id":"T18","span":{"begin":1238,"end":1244},"obj":"Disease"},{"id":"T19","span":{"begin":1387,"end":1405},"obj":"Disease"},{"id":"T20","span":{"begin":1537,"end":1545},"obj":"Disease"},{"id":"T21","span":{"begin":1566,"end":1574},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":218,"end":223},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T2","span":{"begin":291,"end":294},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T3","span":{"begin":424,"end":425},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":709,"end":710},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":1410,"end":1414},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T6","span":{"begin":1415,"end":1416},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T7","span":{"begin":1617,"end":1622},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T8","span":{"begin":1617,"end":1622},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T9","span":{"begin":1617,"end":1622},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T10","span":{"begin":1617,"end":1622},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":211,"end":217},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_37409"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"MeasurableQuantitativeAnnotation","denotations":[{"id":"E1","span":{"begin":802,"end":814},"obj":"entity"},{"id":"E2","span":{"begin":816,"end":846},"obj":"entity"},{"id":"E3","span":{"begin":851,"end":859},"obj":"entity"},{"id":"N1","span":{"begin":891,"end":895},"obj":"num"},{"id":"N2","span":{"begin":898,"end":902},"obj":"num"},{"id":"N3","span":{"begin":908,"end":911},"obj":"num"},{"id":"U1","span":{"begin":895,"end":896},"obj":"unit"},{"id":"U2","span":{"begin":902,"end":903},"obj":"unit"},{"id":"U3","span":{"begin":911,"end":912},"obj":"unit"}],"relations":[{"id":"R1","pred":"associateWith","subj":"E1","obj":"N1"},{"id":"R2","pred":"associateOf","subj":"N1","obj":"U1"},{"id":"R3","pred":"associateWith","subj":"E2","obj":"N2"},{"id":"R4","pred":"associateOf","subj":"N2","obj":"U2"},{"id":"R5","pred":"associateWith","subj":"E3","obj":"N3"},{"id":"R6","pred":"associateOf","subj":"N3","obj":"U3"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":802,"end":814},"obj":"Phenotype"},{"id":"T2","span":{"begin":946,"end":958},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2","span":{"begin":25,"end":58},"obj":"Disease"},{"id":"3","span":{"begin":62,"end":70},"obj":"Disease"},{"id":"32","span":{"begin":164,"end":172},"obj":"Species"},{"id":"33","span":{"begin":211,"end":243},"obj":"Disease"},{"id":"34","span":{"begin":245,"end":253},"obj":"Disease"},{"id":"35","span":{"begin":276,"end":285},"obj":"Disease"},{"id":"36","span":{"begin":347,"end":380},"obj":"Disease"},{"id":"37","span":{"begin":405,"end":413},"obj":"Disease"},{"id":"38","span":{"begin":494,"end":527},"obj":"Disease"},{"id":"39","span":{"begin":531,"end":539},"obj":"Disease"},{"id":"40","span":{"begin":622,"end":630},"obj":"Species"},{"id":"41","span":{"begin":742,"end":750},"obj":"Species"},{"id":"42","span":{"begin":802,"end":814},"obj":"Disease"},{"id":"43","span":{"begin":816,"end":846},"obj":"Disease"},{"id":"44","span":{"begin":851,"end":859},"obj":"Disease"},{"id":"45","span":{"begin":863,"end":871},"obj":"Species"},{"id":"46","span":{"begin":877,"end":885},"obj":"Disease"},{"id":"47","span":{"begin":946,"end":958},"obj":"Disease"},{"id":"48","span":{"begin":960,"end":991},"obj":"Disease"},{"id":"49","span":{"begin":996,"end":1004},"obj":"Disease"},{"id":"50","span":{"begin":1149,"end":1157},"obj":"Species"},{"id":"51","span":{"begin":1163,"end":1171},"obj":"Disease"},{"id":"52","span":{"begin":1191,"end":1205},"obj":"Disease"},{"id":"53","span":{"begin":1230,"end":1244},"obj":"Disease"},{"id":"54","span":{"begin":1285,"end":1293},"obj":"Species"},{"id":"55","span":{"begin":1327,"end":1335},"obj":"Species"},{"id":"56","span":{"begin":1349,"end":1357},"obj":"Species"},{"id":"57","span":{"begin":1372,"end":1405},"obj":"Disease"},{"id":"58","span":{"begin":1537,"end":1545},"obj":"Disease"},{"id":"59","span":{"begin":1566,"end":1574},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"tao:has_database_id","subj":"2","obj":"MESH:D002318"},{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:C000657245"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"Tax:9606"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:C000657245"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:C000657245"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:D007239"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"MESH:D002318"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:C000657245"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:D002318"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:C000657245"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:9606"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"Tax:9606"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D006973"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D002561"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D003920"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"Tax:9606"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:C000657245"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D006973"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D002561"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:D003920"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:9606"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:C000657245"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:D006331"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D006331"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:9606"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:9606"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:9606"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D002318"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:C000657245"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":80},"obj":"Sentence"},{"id":"T2","span":{"begin":81,"end":92},"obj":"Sentence"},{"id":"T3","span":{"begin":93,"end":286},"obj":"Sentence"},{"id":"T4","span":{"begin":287,"end":414},"obj":"Sentence"},{"id":"T5","span":{"begin":415,"end":423},"obj":"Sentence"},{"id":"T6","span":{"begin":424,"end":645},"obj":"Sentence"},{"id":"T7","span":{"begin":646,"end":699},"obj":"Sentence"},{"id":"T8","span":{"begin":700,"end":708},"obj":"Sentence"},{"id":"T9","span":{"begin":709,"end":782},"obj":"Sentence"},{"id":"T10","span":{"begin":783,"end":927},"obj":"Sentence"},{"id":"T11","span":{"begin":928,"end":1134},"obj":"Sentence"},{"id":"T12","span":{"begin":1135,"end":1206},"obj":"Sentence"},{"id":"T13","span":{"begin":1207,"end":1336},"obj":"Sentence"},{"id":"T14","span":{"begin":1337,"end":1348},"obj":"Sentence"},{"id":"T15","span":{"begin":1349,"end":1546},"obj":"Sentence"},{"id":"T16","span":{"begin":1547,"end":1623},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.\nBACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.\nMETHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.\nRESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.\nCONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."}